| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 207.0 | 237.9 | 196.0 |
| Other income | 1.7 | 2.6 | 0.6 |
| Total income | 208.7 | 240.5 | 196.6 |
| Profit before exceptional items & tax | 27.2 | 27.1 | 24.4 |
| Profit before tax | 27.2 | 27.1 | 24.4 |
| Net profit | 20.9 | 32.7 | 20.5 |
| Operating margin | 13.0% | 11.3% | 12.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +2.00% |
|---|---|
| Net profit, quarter on quarter | -36.10% |
| Revenue, year on year | +5.60% |
| Operating profit, year on year | -3.50% |
| Operating profit, quarter on quarter | -36.20% |
NSE results filing, NSE: SMSPHARMA. Figures extracted from the filing.
SMS Pharmaceuticals Ltd: key numbers
- Share price
- ₹475.00
- Market cap
- ₹4,211 Cr
- Revenue (annual)
- ₹886.9 Cr
- Net profit (annual)
- ₹102.0 Cr
- P/E (TTM)
- 41.1×Sector 50.4×
- Promoter holding
- 68.07%+0.00% QoQ
- FII holding
- 0.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from SMS Pharmaceuticals Ltd
All →SMS Pharmaceuticals Other Announcement
SMS Pharmaceuticals disclosed two market sell trades by Designated Person NVV Satyanarayana totalling ₹0.14 Crore. The PIT Reg 7(2) intimation involves a non-promoter designated person.
- Value
- ₹0.14 Cr
SMS Pharmaceuticals Annual General Meeting
SMS Pharmaceuticals Limited has scheduled its 38th Annual General Meeting for September 29, 2026. Key agenda items include dividend declaration, management re-appointments, and approval of material related party transactions.
SMS Pharmaceuticals Annual Report
SMS Pharmaceuticals Limited has released its Annual Report and Notice for the 38th Annual General Meeting scheduled for September 29, 2026. The company reported FY26 revenue of ₹887 Crore.
SMS Pharmaceuticals Credit Rating
CARE Ratings Limited has reaffirmed or revised the credit ratings for SMS Pharmaceuticals Limited's bank facilities. The review covers the company's long-term and short-term credit facilities.
SMS Pharmaceuticals Investor Presentation: Key Takeaways
SMS Pharma reported Q1FY27 revenue of ₹207 Cr (+6% YoY) with stable EBITDA margins at ~20%. Strategy focuses on high-value APIs and peptide R&D.
SMS Pharmaceuticals Earnings Call: Key Takeaways
SMS Pharma delivered FY26 revenue of ₹887cr (+13%) and PAT of ₹102cr (+47%). Strategy focuses on backward integration and high-margin API expansion.